Oramed Pharmaceuticals Inc (ORMP)

[midastouch017]

Oramed Pharmaceuticals (NASDAQ:ORMP) Research Coverage Started at National Securities


https://www.marketbeat.com/instant-alerts/nasdaq-ormp-a-buy-or-sell-right-now-2021-02/

TUESDAY, FEBRUARY 9, 2021 | MARKETBEAT

Oramed Pharmaceuticals logoResearch analysts at National Securities assumed coverage on shares of Oramed Pharmaceuticals (NASDAQ:ORMP) in a research report issued on Tuesday, Briefing.com reports. The firm set a "buy" rating on the biotechnology company's stock.

Several other equities research analysts have also recently issued reports on ORMP. Alliance Global Partners assumed coverage on shares of Oramed Pharmaceuticals in a research note on Thursday, December 3rd. They set a "buy" rating and a $11.00 target price on the stock. Aegis boosted their price target on shares of Oramed Pharmaceuticals from $6.00 to $12.00 and gave the stock a "buy" rating in a research report on Wednesday, January 27th.

NASDAQ:ORMP opened at $10.43 on Tuesday. Oramed Pharmaceuticals has a 12 month low of $2.40 and a 12 month high of $11.40. The stock has a 50 day moving average of $5.59 and a two-hundred day moving average of $3.84. The firm has a market cap of $306.33 million, a P/E ratio of -17.98 and a beta of 1.98.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its quarterly earnings results on Wednesday, January 13th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.14) by ($0.09). Oramed Pharmaceuticals had a negative return on equity of 45.93% and a negative net margin of 424.76%. The firm had revenue of $0.67 million during the quarter. Analysts anticipate that Oramed Pharmaceuticals will post -0.94 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in the stock. WINTON GROUP Ltd acquired a new position in Oramed Pharmaceuticals during the third quarter worth $74,000. GSA Capital Partners LLP purchased a new position in shares of Oramed Pharmaceuticals during the 3rd quarter worth $51,000. BlackRock Inc. raised its holdings in shares of Oramed Pharmaceuticals by 23.5% during the 3rd quarter. BlackRock Inc. now owns 89,001 shares of the biotechnology company's stock worth $232,000 after acquiring an additional 16,963 shares during the period. Phoenix Holdings Ltd. boosted its position in shares of Oramed Pharmaceuticals by 8.5% during the 3rd quarter. Phoenix Holdings Ltd. now owns 197,763 shares of the biotechnology company's stock valued at $483,000 after acquiring an additional 15,503 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of Oramed Pharmaceuticals by 59.4% in the third quarter. Jane Street Group LLC now owns 32,735 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 12,193 shares during the period. Hedge funds and other institutional investors own 6.03% of the company's stock.